Progress reported with candidate dengue vaccine
Trials in Thailand with a candidate vaccine for dengue, a potentially fatal mosquito-borne disease, have shown it to protect against three of the four virus strains, its French maker said Wednesday.
The first trials in humans proved the vaccine was safe and represented a key milestone in the quest for a dengue jab, vaccine-maker Sanofi Pasteur executive vice president Michel De Wilde said in a statement.
"This is also an important development for global public health, since there is currently no specific treatment or prevention for dengue."
The World Health Organisation says the disease infects between 50 million and 100 million people every year and kills more than 20,000 -- mainly in tropical and subtropical regions of Asia and Latin America, but expanding rapidly including to parts of Europe.
Researchers estimate that some three billion people live in regions susceptible to dengue contagion and another 20 million tourists pass through them.
The disease caused by one of four virus serotypes results in fever, aches, rashes, vomiting and in rare cases death. Children are especially vulnerable.
Sanofi Pasteur said its candidate vaccine was effective against three of the four virus serotypes and analyses were under way "to understand the lack of protection for the fourth".
The company conducted trials on 4,000 children aged four to 11 in Thailand's Muang district, the results of which have yet to be published in a peer-reviewed medical journal.
Larger Phase III trials with 31,000 adults and children are taking place in 10 countries in Asia and Latin America.
(c) 2012 AFP
- Dengue vaccine could be ready by 2015: Sanofi Jun 10, 2011 | not rated yet | 0
- Thailand developing dengue vaccine: researcher Feb 22, 2011 | not rated yet | 0
- Capacity of developing country NRAs key to accelerated introduction of upcoming dengue vaccines Feb 22, 2011 | not rated yet | 0
- Human clinical trial of NIH-developed dengue vaccine begins Aug 09, 2010 | not rated yet | 0
- Human antibody for dengue virus isolated Jun 22, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications 10 hours ago | not rated yet | 0
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications May 23, 2013 | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications May 23, 2013 | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
11 hours ago | 5 / 5 (2) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
2 hours ago | not rated yet | 0
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
10 hours ago | not rated yet | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
10 hours ago | not rated yet | 0
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
May 20, 2013 | 4.8 / 5 (30) | 9 |